ABSTRACT
To directly target the posterior eye chamber, a common method of therapy is intravitreal injection (IVT) to deliver drugs to the retina [1,2]. This method is not without any adverse side effects; the common ones include tissue damage and infections [1]. Nonbiodegradable forms of treatment are also used, by which a nanosized device is surgically implanted at the site of therapy [3]. The drawbacks of such a method are the relative large-sized incision required to implant a device; the repeated implantations of a new device, once the previous device has exhausted its drug supply; and neglecting removal of the device may cause it to be encapsulated by the brous tissue [3]. The possible complications with this type of therapy include retinal detachment, vitreous hemorrhage, and dissolution of the device, among others [3].
